Soleo Health Named Exclusive Specialty Pharmacy for Qfitlia™ in Hemophilia Treatment
Bringing a first-in-class antithrombin-lowering therapy to patients with hemophilia A or B, Soleo Health reinforces its leadership in specialty pharmacy services through a strategic collaboration with Sanofi.
In a significant move underscoring its commitment to delivering complex specialty therapies to patients with rare and chronic conditions, Soleo Health, a national leader in the specialty pharmacy space, has been selected by Sanofi, the global biopharmaceutical giant, as the exclusive in-network specialty pharmacy provider for Qfitlia™ (fitusiran). This announcement comes on the heels of the U.S. Food and Drug Administration’s (FDA) recent approval of Qfitlia, an innovative therapy that marks a groundbreaking advancement in the management of hemophilia A and B, with or without factor VIII or IX inhibitors.
Qfitlia (fitusiran) is the first-ever antithrombin-lowering treatment approved for routine prophylaxis in patients aged 12 and older who are living with hemophilia A or B. This milestone not only introduces a novel therapeutic option for individuals affected by this life-threatening bleeding disorder but also highlights the increasing importance of specialty pharmacies in navigating complex care and treatment access for rare diseases.
A Milestone in Hemophilia Treatment
Hemophilia is a rare genetic bleeding disorder that impairs the blood’s ability to clot, leading to spontaneous or excessive bleeding following injuries or surgical procedures. It primarily affects males and can result in severe complications such as joint damage, organ bleeding, and life-threatening hemorrhages if not properly managed. Hemophilia A, the most common type, is caused by a deficiency in clotting factor VIII, while hemophilia B stems from a deficiency in clotting factor IX.
Traditional treatment for hemophilia has long relied on replacement therapies involving intravenous infusions of the missing clotting factor. While effective, these therapies often require frequent administration and are associated with the risk of developing inhibitors—neutralizing antibodies that render treatment less effective or even ineffective.
Qfitlia introduces an entirely different mechanism of action. As an RNA interference (RNAi) therapeutic, it works by targeting the liver to reduce the production of antithrombin, a natural anticoagulant protein. By lowering antithrombin levels, Qfitlia enhances thrombin generation, thereby rebalancing hemostasis in patients with hemophilia, irrespective of inhibitor status. This approach represents a major paradigm shift in the treatment landscape and offers hope for improved disease control and quality of life.
Soleo Health: Driving Patient Access and Support
The selection of Soleo Health as the exclusive in-network specialty pharmacy for Qfitlia is not just a strategic business move—it’s a reflection of the organization’s deep expertise in managing complex, high-touch therapies and navigating the clinical, financial, and logistical hurdles that often accompany treatment for rare diseases.
“Soleo Health is honored to be chosen by Sanofi to support the launch and distribution of Qfitlia,” said Drew Walk, Chief Executive Officer of Soleo Health. “Therapies like Qfitlia can have a profound impact on the lives of patients living with hemophilia, and we are committed to helping ensure they receive timely access to this first-of-its-kind treatment. Our team’s collaborative approach with biopharmaceutical partners ensures patients receive comprehensive clinical support, coordinated care, and high-quality service that improves outcomes.”
As part of its role, Soleo Health will oversee clinical management, patient education, product delivery, reimbursement support, and ongoing monitoring for those receiving Qfitlia. This holistic, patient-centric model aims to reduce treatment barriers, facilitate adherence, and ultimately enhance the therapeutic experience for individuals with hemophilia.
With more than 30 pharmacy and infusion service locations across the U.S., Soleo Health has a national footprint that enables personalized care at scale. The company is known for its data-driven, outcomes-focused approach and its ability to handle the nuances of rare, ultra-rare, and complex conditions—including neuromuscular disorders, immunologic diseases, oncology, and gene therapies.
Sanofi’s Commitment to Hematology Innovation
The FDA’s approval of Qfitlia and its subsequent launch through Soleo Health mark a new chapter in Sanofi’s growing hematology portfolio. As a company deeply invested in developing transformative therapies for rare and serious diseases, Sanofi has consistently demonstrated its commitment to addressing unmet needs in hemophilia and other bleeding disorders.
“Patients with hemophilia have long needed more flexible, effective treatment options that do not rely solely on factor replacement therapy,” noted a representative from Sanofi. “Qfitlia represents a significant step forward in reimagining care by leveraging RNAi technology to target the underlying biology of the disease. Our partnership with Soleo Health ensures that this important advancement reaches patients who need it, supported by expert care and guidance.”
The approval of Qfitlia follows promising clinical trial data demonstrating its ability to significantly reduce the frequency of bleeding episodes in both hemophilia A and B patients, regardless of inhibitor status. This broad indication sets Qfitlia apart from many existing therapies and positions it as a valuable tool in the evolving therapeutic arsenal.
A Transformative Future for Patients
The impact of Qfitlia’s introduction—and Soleo Health’s involvement—extends beyond clinical efficacy. For many patients and caregivers, the complexity of managing hemophilia involves not just medical concerns but also emotional, logistical, and financial challenges.
By streamlining treatment access and providing a high-touch care experience, Soleo Health plays a pivotal role in transforming what might otherwise be an overwhelming journey into one that is manageable and supported. From medication education and side-effect monitoring to financial navigation and insurance coordination, Soleo Health serves as a trusted partner throughout the patient care continuum.
Moreover, the collaboration signals an important shift in how pharmaceutical companies and specialty pharmacies are working together to enable equitable access to innovative therapies—especially in the field of rare disease, where tailored care delivery is essential.
The announcement that Soleo Health will serve as the exclusive in-network specialty pharmacy for Sanofi’s newly approved Qfitlia (fitusiran) is a milestone event for the hemophilia community. As the first and only antithrombin-lowering therapy approved by the FDA for hemophilia A and B patients aged 12 and older, Qfitlia represents a cutting-edge treatment approach that may transform patient care.
Through this partnership, Soleo Health reaffirms its leadership in the specialty pharmacy space and continues to advance its mission of connecting patients with complex conditions to the innovative therapies they need. With a shared vision for improved outcomes and enhanced quality of life, Soleo Health and Sanofi are charting a new course in hemophilia care—one defined by scientific innovation, personalized support, and patient-centered delivery.
As Qfitlia becomes available across the country, the collaboration between these two industry leaders promises to bring new hope and possibilities to thousands of individuals and families affected by hemophilia.
